Stock Analiz

Instil Bio, Inc. TIL

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026

$6.08Market cap $41M
Open the interactive analysis →

Instil Bio, Inc. (TIL) is a healthcare company listed in the US with a market value of about $41M. In the twelve months to June 30, 2026 it had revenue of $9M and net income of -$30M, a net margin of -337.7%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 130% a year, a 5-year average ROIC of -51%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 31% below the current price.

About Instil Bio

Instil Bio is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. Revenue went from $138000 in 2020 to $9M in 2025, growth of about 130.4% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 3% over three years (dilution for shareholders). It spends 276% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth3/5
Track record1/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S4.6
P/B0.4
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−31%

Growth and quality

Revenue growth (1 yr)110.2%
Revenue growth (5 yrs, per year)130.4%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1266.6%
ROIC (5-yr avg.)-50.8%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$9M$9M$4M$0—$0$138000
Net income-$30M-$71M-$74M-$156M-$223M-$157M-$38M
Free cash flow——-$56M-$103M-$265M-$180M-$80M
EPS (diluted)$-4.43$-10.70$-11.39$-24.00$-34.46$-29.60$-47.20
Net margin-337.7%-795.9%-1737.4%———-27346.4%
ROIC—-68.8%-33.8%-69.1%-60.5%-22.1%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Instil Bio stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 31% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Instil Bio pay a dividend?

Not currently.

Is Instil Bio a good stock to buy?

We do not give buy or sell advice. Instil Bio scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.